International Journal of

Rare Diseases and DisordersISSN: 2643-4571

Early Online

 Open Access DOI:10.23937/2643-4571/1710022

Case Report: Tolosa-Hunt Syndrome Associated with a Chest Mass in a Pediatric Patient

William Im, Marla Sacks, Laura Goodman and Andrei Radulescu

Article Type: Case Report | First Published: October 02, 2020

Tolosa-Hunt Syndrome is a rare disease with an incidence rate of about one in one million per year worldwide. It is caused by granulomatous, nonspecific inflammation of the cavernous sinus, which results in severe headaches, eye pain, and ophthalmoplegia. This is the case of a previously healthy 10-year-old male with a family history significant for Non-Hodgkin’s Lymphoma and Squamous cell carcinoma who presented to the Emergency Department (ED) with an intense recurring headache and ophthalmo...

 Open Access DOI:10.23937/2643-4571/1710021

A Rare Case of Raised Alkaline Phosphatase - Polyostotic Fibrous Dysplasia

Dhanuja Senn and Mehdi Mirzazadeh

Article Type: Case Report | First Published: October 02, 2020

Fibrous dysplasia is an uncommon, bone development abnormality characterized by the replacement of normal cancellous bone by fibrous tissue and immature woven bone. Classified according to the number of affected bones, fibrous dysplasia can affect any bones of the skeletal system, with long bones the most commonly documented site of involvement. Typically, diagnosis is based on clinical, radiological and histological findings. However, due to its broad clinical spectrum, it remains a therapeutic...

 Open Access DOI:10.23937/2643-4571/1710020

Clinical Characteristics and Prognostic Factors in Patients with Hemophagocytic Syndrome

César Antonio Egües Dubuc, MD, Jaime Calvo-Alen, MD, PhD, Lizbeth Patricia Cabrera-Miranda, MD, Andrea De Diego Sola, MD, José Ramon Furundarena Salsamendi, MD, Nerea Alcorta Lorenzo, MD, Jesús Alejandro Valero Jaimes, MD, Luis María López Dominguez, MD, Jorge Jesús Cancio Fanlo, MD, Olga Maiz Alonso, MD, Esther Uriarte Isacelaya, MD and Joaquín María Belzunegui Otano, MD

Article Type: Original Article | First Published: September 09, 2020

The mortality rate of Hemophagocytic Syndrome (HPS) is 26.5%-74.8%. Malignant neoplasms, hyperferritinemia, thrombocytopenia, older age, hypertriglyceridemia, and prolonged prothrombin are considered to be adverse prognostic factors. This study describes the underlying features of patients survivors and non-survivors with HPS from one hospital between 2005-2019. This is a retrospective study. We included patient with HPS diagnosis based on the HLH-2004 criteria, or who presented hemophagocytic c...

 Open Access DOI:10.23937/2643-4571/1710019

COVID -19 Pandemic and Level of Responses in Bangladesh

Md Kariul Islam, MSS, MPH, Md Shukur Ali, PhD, SAM Ziaur Rahman Akanda, MSc, Shahnaz Rahman, BA, AHM Kamruzzaman, MBA, DBA, Sharif Abdul Kader Pavel, MPH and Jannatul Baki, MBA

Article Type: Review Article | First Published: August 24, 2020

Bangladesh is a South East Asian natural beautiful middle income country. Its economy is flourishing rapidly. In the last decade immense development has been noticed in every sphere of life including women empowerment. However, incidence of COVID-19 Pandemic has influenced every sector of Bangladesh badly. The area of Bangladesh is about 1,47,570s km and about 160 million people live here with peace and amity. Naturally, the density of population of this country is very high in comparing to some...

 Open Access DOI:10.23937/2643-4571/1710017

A Solution for the Treatment of a Neglected Subset of Rare Diseases

Grant E Fisher

Article Type: Position Statement | First Published: May 07, 2020

Individual HRDs are made up of small patient populations, thus the high individual prices will amount to a relatively small total cost to insurers and the healthcare system overall. Treatments for HRDs will, in almost all cases, represent the first and only available treatments. As the collective price will not be problematic and with treatments being the first available, insurers will have an incentive to cover the prices necessary to develop and commercialize these therapies....

 Open Access DOI:10.23937/2643-4571/1710018

Non-biopsy Diagnosis of Hereditary Transthyretin Amyloidosis Presented with Cardiomyopathy and Peripheral Neuropathy in a Chinese Man in Hong Kong

Mei Han Ho, MBBS, MRes (Med), MRCP, Pui Lun Yip, MB, ChB, FHKAM (Med), Cheuk Bong Ho, MBBS, MRCP, Felix Chi Kin Wong, MBBS, MHKC (Path), Sammy Pak Lam Chen, FRCPA, FHKAM (Pathology) and Chi Yuen Wong, FHKCP, FHKAM (Med)

Article Type: Case Report | First Published: May 16, 2020

Amyloidosis is a rare disease characterized by deposition of misfolded amyloid protein, which commonly affects myocardium, nerves, kidneys and various organs. The clinical presentation is highly variable. We herein describe, to our knowledge, the first case of a Chinese man with hereditary transthyretin related cardiac amyloidosis (ATTR) with Ala117Ser mutation in Hong Kong who presented with peripheral neuropathy and congestive heart failure. Echocardiography showed left ventricular hypertrophy...

 Open Access DOI:10.23937/2643-4571/1710016

Rare Diseases in Mediaeval Europe

Dooms M

Article Type: Review Article | First Published: March 28, 2020

Monastic rules made an end to infanticide and child neglect in the Middle-Ages by caring for children with (rare) disorders: Disabled and impaired citizens became part of daily life. Historic, paleo-pathological, iconographic and genetic research revealed several cases of acromegaly, achondroplasia, alpha-1-antitrypsin deficiency, cystic fibrosis, Down syndrome, Dupuytren’s contraction, goiter, Marfan syndrome, Paget’s disease and phenylketonuria. These observations want to illustrate that d...

 Open Access DOI:10.23937/2643-4571/1710014

Case Series Synopsis: Gaucher Disease Type 1 Patients Treated with Eliglustat over 6 Years

Cristina Fraga, Sonia Medeiros, Sara Serpa and David Silva

Article Type: Case Series | First Published: January 08, 2020

Gaucher disease (GD) type 1 is a lysosomal storage disorder associated with bone disease, hepatosplenomegaly, anemia and thrombocytopenia. Here we present a case series from 5 (3 females and 2 males) Portuguese individuals from a single institution with GD type 1 who were treated with substrate-reduction therapy (eliglustat, 84 mg once or twice daily) for 6-years. Four cases were switched from IV imiglucerase (28 U/kg q2 week [n = 1]) or 45 U/kg q2 week [n = 3]) and one was enzyme-replacement th...

Volume 3
Issue 1